Selecting drug candidates that are most likely to succeed in the clinic is crucial in order to reduce the costs and time involved in drug discovery and development. Preclinical imaging can improve these odds by providing powerful insights into drug efficacy, biodistribution, toxicology and therapeutic responses early in the process. This white paper examines how in vivo imaging can help provide go/no-go decisions earlier, de-risk potential drug candidates, shorten the time to clinical and reduce development costs.